Cardiac PDEs and Crosstalk Between CAMP and CGMP Signalling Pathways in the Regulation of Contractility

Overview

Journal Naunyn Schmiedebergs Arch Pharmacol

Specialty Pharmacology

Date 2013 May 8

PMID 23649864

Citations 13

Authors

Finn Olav Levy

Affiliations

Soon will be listed here.

Abstract

Elucidation of cAMP and cGMP signalling in the heart remains a hot topic, and new regulatory mechanisms continue to appear. Studying the influence of phosphodiesterases on 5-HT4 receptor signalling in porcine atrium, a paper from this issue of the journal expands findings of a crosstalk between cardiac cGMP and cAMP signalling recently discovered in failing rat ventricle to a different species and cardiac region. The overall data suggest that cGMP, produced following stimulation of the NPR-B receptor for C-type natriuretic peptide (CNP), inhibits cAMP degradation by phosphodiesterase 3 and thereby enhances cAMP-mediated signalling from β-adrenoceptors and 5-HT4 receptors to inotropic effects. In porcine atrium, this effect can be seen both as an increase in inotropic effect and as a reduced fade of the inotropic effect with time. Thus, accumulating evidence brings together several active fields of research, including cardiac phosphodiesterases, compartmentation of cyclic nucleotide signalling and the field of natriuretic peptides. If present in human hearts, this effect of CNP may have clinical implications.

Citing Articles

Cyclic GMP and PKG Signaling in Heart Failure.

Numata G, Takimoto E Front Pharmacol. 2022; 13:792798.

PMID: 35479330 PMC: 9036358. DOI: 10.3389/fphar.2022.792798.

Phosphodiesterases and Compartmentation of cAMP and cGMP Signaling in Regulation of Cardiac Contractility in Normal and Failing Hearts.

Calamera G, Moltzau L, Levy F, Andressen K Int J Mol Sci. 2022; 23(4).

PMID: 35216259 PMC: 8880502. DOI: 10.3390/ijms23042145.

FRET-based cyclic GMP biosensors measure low cGMP concentrations in cardiomyocytes and neurons.

Calamera G, Li D, Ulsund A, Kim J, Neely O, Moltzau L Commun Biol. 2019; 2:394.

PMID: 31701023 PMC: 6820734. DOI: 10.1038/s42003-019-0641-x.

Mind the gap (junction): cGMP induced by nitric oxide in cardiac myocytes originates from cardiac fibroblasts.

Menges L, Krawutschke C, Fuchtbauer E, Fuchtbauer A, Sandner P, Koesling D Br J Pharmacol. 2019; 176(24):4696-4707.

PMID: 31423565 PMC: 6965686. DOI: 10.1111/bph.14835.

Soluble Guanylate Cyclase Agonists Induce Bronchodilation in Human Small Airways.

Koziol-White C, Ghosh A, Sandner P, Erzurum S, Stuehr D, Panettieri Jr R Am J Respir Cell Mol Biol. 2019; 62(1):43-48.

PMID: 31340135 PMC: 6938135. DOI: 10.1165/rcmb.2019-0001OC.

References

Kaumann A, Levy F . Fading of 5-HT4 receptor-mediated inotropic responses to 5-hydroxytryptamine is caused by phosphodiesterase activity in porcine atrium. Br J Pharmacol. 2005; 147(2):128-30. PMC: 1615854. DOI: 10.1038/sj.bjp.0706501. View

Butcher R, SUTHERLAND E . Adenosine 3',5'-phosphate in biological materials. I. Purification and properties of cyclic 3',5'-nucleotide phosphodiesterase and use of this enzyme to characterize adenosine 3',5'-phosphate in human urine. J Biol Chem. 1962; 237:1244-50. View

Kaumann A, Levy F . 5-hydroxytryptamine receptors in the human cardiovascular system. Pharmacol Ther. 2006; 111(3):674-706. DOI: 10.1016/j.pharmthera.2005.12.004. View

SUTHERLAND E, RALL T . Fractionation and characterization of a cyclic adenine ribonucleotide formed by tissue particles. J Biol Chem. 1958; 232(2):1077-91. View

Mongillo M, McSorley T, Evellin S, Sood A, Lissandron V, Terrin A . Fluorescence resonance energy transfer-based analysis of cAMP dynamics in live neonatal rat cardiac myocytes reveals distinct functions of compartmentalized phosphodiesterases. Circ Res. 2004; 95(1):67-75. DOI: 10.1161/01.RES.0000134629.84732.11. View

Nikolaev V, Moshkov A, Lyon A, Miragoli M, Novak P, Paur H . Beta2-adrenergic receptor redistribution in heart failure changes cAMP compartmentation. Science. 2010; 327(5973):1653-7. DOI: 10.1126/science.1185988. View

. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999; 353(9146):9-13. View

Vargas M, Hernandez J, Kaumann A . Phosphodiesterase PDE3 blunts the positive inotropic and cyclic AMP enhancing effects of CGP12177 but not of noradrenaline in rat ventricle. Br J Pharmacol. 2005; 147(2):158-63. PMC: 1615855. DOI: 10.1038/sj.bjp.0706498. View

Kaumann A, Sanders L, Brown A, Murray K, Brown M . A 5-hydroxytryptamine receptor in human atrium. Br J Pharmacol. 1990; 100(4):879-85. PMC: 1917575. DOI: 10.1111/j.1476-5381.1990.tb14108.x. View

10.

Zaccolo M, Pozzan T . Discrete microdomains with high concentration of cAMP in stimulated rat neonatal cardiac myocytes. Science. 2002; 295(5560):1711-5. DOI: 10.1126/science.1069982. View

11.

Rossmanith G, Hoh J, Turnbull L, Ludowyke R . Mechanism of action of endothelin in rat cardiac muscle: cross-bridge kinetics and myosin light chain phosphorylation. J Physiol. 1997; 505 ( Pt 1):217-27. PMC: 1160106. DOI: 10.1111/j.1469-7793.1997.217bc.x. View

12.

Hussain R, Qvigstad E, Birkeland J, Eikemo H, Glende A, Sjaastad I . Activation of muscarinic receptors elicits inotropic responses in ventricular muscle from rats with heart failure through myosin light chain phosphorylation. Br J Pharmacol. 2009; 156(4):575-86. PMC: 2697711. DOI: 10.1111/j.1750-3639.2009.00016.x. View

13.

Zaccolo M, De Giorgi F, Cho C, Feng L, Knapp T, Negulescu P . A genetically encoded, fluorescent indicator for cyclic AMP in living cells. Nat Cell Biol. 2000; 2(1):25-9. DOI: 10.1038/71345. View

14.

Jahnel U, Rupp J, Ertl R, Nawrath H . Positive inotropic response to 5-HT in human atrial but not in ventricular heart muscle. Naunyn Schmiedebergs Arch Pharmacol. 1992; 346(5):482-5. DOI: 10.1007/BF00169000. View

15.

Redfield M, Chen H, Borlaug B, Semigran M, Lee K, Lewis G . Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA. 2013; 309(12):1268-77. PMC: 3835156. DOI: 10.1001/jama.2013.2024. View

16.

Brattelid T, Qvigstad E, Lynham J, Molenaar P, Aass H, Geiran O . Functional serotonin 5-HT4 receptors in porcine and human ventricular myocardium with increased 5-HT4 mRNA in heart failure. Naunyn Schmiedebergs Arch Pharmacol. 2004; 370(3):157-66. DOI: 10.1007/s00210-004-0963-0. View

17.

Cohn J, Goldstein S, GREENBERG B, Lorell B, Bourge R, Jaski B . A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators. N Engl J Med. 1998; 339(25):1810-6. DOI: 10.1056/NEJM199812173392503. View

18.

Verde I, Vandecasteele G, Lezoualch F, Fischmeister R . Characterization of the cyclic nucleotide phosphodiesterase subtypes involved in the regulation of the L-type Ca2+ current in rat ventricular myocytes. Br J Pharmacol. 1999; 127(1):65-74. PMC: 1565993. DOI: 10.1038/sj.bjp.0702506. View

19.

. Xamoterol in severe heart failure. The Xamoterol in Severe Heart Failure Study Group. Lancet. 1990; 336(8706):1-6. View

20.

Schoemaker R, Du X, Bax W, Bos E, Saxena P . 5-Hydroxytryptamine stimulates human isolated atrium but not ventricle. Eur J Pharmacol. 1993; 230(1):103-5. DOI: 10.1016/0014-2999(93)90417-g. View